Improved survival with combination oxaliplatin, irinotecan, cetuximab for metastatic pancreatic cancer

被引：0
|
作者：
Lee, F. [1 ]
Roach, M. [1 ]
Duong, L. [1 ]
Heywood, G. [1 ]
Parasher, G. [1 ]
Rasila, K. [1 ]
机构：
[1] Univ New Mexico, Albuquerque, NM 87131 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2007年 / 25卷 / 18期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
15180
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Clinical predictors of severe toxicity in patients treated with combination chemotherapy with irinotecan and/or oxaliplatin for metastatic colorectal cancer
    Diaz, Roberto
    Aparicio, Jorge
    Molina, Jorge
    Palomar, Laura
    Gimenez, Alejandra
    Ponce, Jose
    Segura, Angel
    Gomez-Codina, Jose
    MEDICAL ONCOLOGY, 2006, 23 (03) : 347 - 357
  • [42] Drug use evaluation of oxaliplatin and irinotecan in metastatic colorectal cancer
    Llopis-Salvia, Pilar
    Sarrio-Montes, Gema
    Sanchez-Castellon, Agueda
    PHARMACY WORLD & SCIENCE, 2009, 31 (01): : 138 - 138
  • [43] Cost-effectiveness of cetuximab in combination with irinotecan compared with current care in metastatic colorectal cancer after failure on irinotecan - A Belgian analysis
    Annemans, L.
    Van Cutsem, E.
    Humblet, Y.
    Van Laethem, J. -L.
    Bleiberg, H.
    ACTA CLINICA BELGICA, 2007, 62 (06) : 419 - 425
  • [44] Impact of Irinotecan and Oxaliplatin on Overall Survival in Patients With Metastatic Colorectal Cancer: A Population-Based Study
    Lim, Howard J.
    Gill, Sharlene
    Speers, Caroline
    Melosky, Barbara
    Barnett, Jeff
    Fitzgerald, Catherine
    O'Reilly, Susan
    Kennecke, Hagen
    JOURNAL OF ONCOLOGY PRACTICE, 2009, 5 (04) : 153 - 158
  • [45] SURVIVAL IMPACT OF THE INTRODUCTION OF OXALIPLATIN AND IRINOTECAN IN THE TREATMENT OF PATIENTS WITH METASTATIC COLORECTAL CANCER: A SINGLE INSTITUTION EXPERIENCE
    Oliveira, M.
    Dionisio, M.
    Esteves, S.
    Oliveira, J.
    Moreira, A.
    ANNALS OF ONCOLOGY, 2010, 21 : 62 - 63
  • [46] Irinotecan combined with oxaliplatin and S1 in patients with metastatic pancreatic adenocarcinoma
    Nie, K.
    Guo, X.
    Zhou, X.
    Zhang, Z.
    Zhang, C.
    Lan, K.
    Ji, Y.
    ANNALS OF ONCOLOGY, 2019, 30
  • [47] Nanoliposomal irinotecan in metastatic pancreatic cancer Reply
    Chen, Li-Tzong
    Wang-Gillam, Andrea
    Von Hoff, Daniel D.
    Bayever, Eliel
    Belanger, Bruce
    LANCET, 2016, 387 (10032): : 1997 - 1997
  • [48] Cetuximab with irinotecan or oxaliplatin for first-line metastatic colorectal cancer: Effectiveness in the EREBUS cohort compared to pivotal trials.
    Fourrier-Reglat, Annie
    Rouyer, Magali
    Noize, Pernelle
    Bignon, Emmanuelle
    Le Monies, Alise
    Jove, Jeremy
    Monnereau, Alain
    Cunha, Antonio Sa
    Francois, Eric
    Mitry, Emmanuel
    Smith, Denis Michel
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [49] Cetuximab with Irinotecan or Oxaliplatin for 1st-Line Metastatic Colorectal Cancer: Effectiveness in the EREBUS Cohort Compared to Pivotal Trials
    Noize, Pernelle
    Fourrier-Reglat, Annie
    Rouyer, Magali
    Grelaud, Angela
    Bignon, Emmanuelle
    de Sagazan, Alise Le Monies
    Lassalle, Regis
    Jove, Jeremy
    Monnereau, Alain
    Cunha, Antonio Sa
    Francois, Eric
    Mitry, Emmanuel
    Moore, Nicholas
    Smith, Denis
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2013, 22 : 60 - 61
  • [50] Epidermal Growth Factor Receptor Expression Discrepancies in Metastatic Colorectal Cancer Patients Treated with Cetuximab Plus Irinotecan-Based Chemotherapy Refractory to Irinotecan and Oxaliplatin
    Han, Hye-Suk
    Chang, Hee Jin
    Hong, Yong Sang
    Kim, Sun Young
    Lee, Keun Seok
    Jung, Kyung Hae
    DISEASES OF THE COLON & RECTUM, 2009, 52 (06) : 1144 - 1151
12345